A clinical assessment of loading dose tamoxifen for advanced breast carcinoma.
Seventy patients with advanced breast carcinoma were treated with a loading dose regimen of 160 mg Tamoxifen on day 1 followed by a maintenance dose of 20 mg daily from day 2 onwards. Compliance was 100% and only 3 patients developed mild side effects. In 27% regression of disease was observed within 1 month and in 57% within 2 months. This regimen is recommended for routine clinical use.
D000328:Adult; D000368:Aged; D001943:Breast Neoplasms / Q000032:analysis / Q000188:drug therapy* / Q000473:pathology; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008875:Middle Aged; D011960:Receptors, Estrogen / Q000032:analysis; D013629:Tamoxifen / Q000008:administration & dosage* / Q000627:therapeutic use; D013997:Time Factors
D011960:Receptors, Estrogen; D013629:Tamoxifen